BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34658227)

  • 1. Evaluation of the Histopathological Features of Early-stage Invasive Ductal Breast Carcinoma by
    Erol M; Önner H; Eren Karanis Mİ
    Mol Imaging Radionucl Ther; 2021 Oct; 30(3):129-136. PubMed ID: 34658227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of
    Önner H; Coskun N; Erol M; Eren Karanis Mİ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):11-16. PubMed ID: 34991831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of
    Önner H; Coskun N; Erol M; Karanis MIE
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Jul; ():. PubMed ID: 34305044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters.
    Ege Aktas G; Taştekin E; Sarikaya A
    Nucl Med Commun; 2018 Jan; 39(1):83-93. PubMed ID: 29135722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
    Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary Lymph Node-to-Primary Tumor Standard Uptake Value Ratio on Preoperative (18)F-FDG PET/CT: A Prognostic Factor for Invasive Ductal Breast Cancer.
    Kim YH; Yoon HJ; Kim Y; Kim BS
    J Breast Cancer; 2015 Jun; 18(2):173-80. PubMed ID: 26155294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and volume-based parameters of (18F)FDG PET/CT for primary mass and axillary lymph node metastasis in patients with invasive ductal carcinoma: a retrospective analysis in relation to molecular subtype, axillary lymph node metastasis and immunohistochemistry and inflammatory markers.
    Can C; Komek H
    Nucl Med Commun; 2019 Oct; 40(10):1051-1059. PubMed ID: 31365497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harmonized pretreatment quantitative volume-based
    Kitajima K; Miyoshi Y; Sekine T; Takei H; Ito K; Suto A; Kaida H; Daisaki H; Yamakado K
    Hell J Nucl Med; 2020; 23(3):272-289. PubMed ID: 33367302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
    Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
    Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of 18
    Xue J; Zheng J; Guo H; Wang X; Han A
    Mol Clin Oncol; 2015 Jan; 3(1):109-114. PubMed ID: 25469279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships of
    Sengoz T; Karakaya YA; Gultekin A; Yaylali O; Senol H; Yuksel D
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):32-38. PubMed ID: 34991834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.